Second Primary Cancers After Kidney Cancers, and Kidney Cancers as Second Primary Cancers

被引:2
|
作者
Zheng, Guoqiao [1 ,2 ,3 ,4 ]
Sundquist, Kristina [4 ,5 ,6 ,7 ]
Sundquist, Jan [4 ,5 ,6 ,7 ]
Chen, Tianhui [8 ,9 ]
Foersti, Asta [1 ,4 ,10 ,11 ]
Hemminki, Otto [12 ,13 ]
Hemminki, Kari [1 ,2 ,4 ,14 ,15 ]
机构
[1] German Canc Res Ctr, Div Mol Genet Epidemiol, Heidelberg, Germany
[2] German Canc Res Ctr, Div Canc Epidemiol, Neuenheimer Feld 581, D-69120 Heidelberg, Germany
[3] Heidelberg Univ, Fac Med, Heidelberg, Germany
[4] Lund Univ, Ctr Primary Hlth Care Res, Malmo, Sweden
[5] Icahn Sch Med Mt Sinai, Dept Family Med & Community Hlth, New York, NY 10029 USA
[6] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA
[7] Shimane Univ, Sch Med, Dept Funct Pathol, Ctr Community Based Healthcare Res & Educ CoHRE, Matsue, Shimane, Japan
[8] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Canc Prevent, Hangzhou, Peoples R China
[9] Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China
[10] Hopp Childrens Canc Ctr KiTZ, Heidelberg, Germany
[11] German Canc Res Ctr, German Canc Consortium DKTK, Div Pediat Neurooncol, Heidelberg, Germany
[12] Univ Helsinki, Translat Immunol Res Program, Canc Gene Therapy Grp, Helsinki, Finland
[13] Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland
[14] Charles Univ Prague, Biomed Ctr, Fac Med, Plzen, Czech Republic
[15] Charles Univ Prague, Biomed Ctr Pilsen, Plzen, Czech Republic
来源
基金
欧盟地平线“2020”; 瑞典研究理事会;
关键词
Cancer incidence; Relative risk; Second primary cancer; Cancer etiology; Sex difference; RENAL-CELL CARCINOMA; UPPER URINARY-TRACT; UROTHELIAL CARCINOMA; RISK; STRATEGIES; NEOPLASMS;
D O I
10.1016/j.euros.2020.12.007
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Second primary cancers (SPCs) are increasing due to improving survival in first primary cancers. Previous studies on SPCs in renal cell carcinoma (RCC) have focused on treatment and other risk factors, but data of RCC as an SPC are scarce. Objective: In this study, we want to elucidate the risk for any SPC after RCC, and in reverse order, for RCC as an SPC after any cancer. We additionally consider how family histories influence the risks. Design, setting, and participants: Patient data were obtained from the Swedish Cancer Registry from years 1990 through 2015, and family data were obtained from the Multigeneration Register. Outcome measurements and statistical analysis: We employed standardized incidence ratios to estimate bidirectional relative risks of subsequent cancer associated with RCC. Results and limitations: We identified 17 587 RCCs (60% in male patients). The highest increases for SPCs were observed for nervous system hemangioblastoma (HB; 26.8), adrenal (12.09) tumors, and renal pelvic cancer (6.32). In the reverse order, RCC as an SPC, nervous system HB (17.01), and adrenal tumors (15.34) were associated with the highest risks. Risks for many other sites (12 sites and subsites) were increased bidirectionally. For women, a total of seven sites and subsites were increased bidirectionally, and many were shared with men. The only significant sex difference in SPCs was the higher lung cancer risk in women (2.41) than in men (1.28). Patients with a family history of HBs or of prostate, colorectal and lung cancers showed high risks of these cancers as SPCs after RCC. Family history accounted for 30% of prostate cancers after RCC. Conclusions: The bidirectional study design was able to suggest risk factors for SPCs and offered a clinical take-home message urging to consider strategies for early detection and prevention of SPCs. Readily available information on lifestyle (eg, smoking) and family history (eg, prostate cancer) may reveal targets for risk reduction with prognostic benefits. Patient summary: Close to 10% of kidney cancer patients develop another cancer. The cause for these other cancers may not depend on kidney cancer. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.
引用
收藏
页码:52 / 59
页数:8
相关论文
共 50 条
  • [31] Second primary breast and thyroid cancers (Israel)
    Siegal Sadetzki
    Ronit Calderon-Margalit
    Chava Peretz
    Ilya Novikov
    Micha Barchana
    Moshe Z. Papa
    [J]. Cancer Causes & Control, 2003, 14 : 367 - 375
  • [32] Risk factors predicting second primary cancers
    Snow, GB
    Cloos, J
    Bongers, V
    Copper, MP
    Braakhuis, BJM
    [J]. HEAD AND NECK CANCER, VOL 4, 1996, : 639 - 644
  • [33] Characteristics of metachronous second primary lung cancers
    Dogan, Coskun
    Fidan, Ali
    Kiral, Nesrin
    Parmaksiz, Elif Torun
    Salepci, Banu
    Caglayan, Benan
    Comert, Sevda Sener
    [J]. EURASIAN JOURNAL OF PULMONOLOGY, 2019, 21 (02) : 127 - 131
  • [34] Second primary breast and thyroid cancers.
    Sadetzki, S
    Calderon, R
    Peretz, C
    Novikov, I
    Barchana, M
    Papa, MZ
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 155 (11) : s18 - s18
  • [35] Second primary cancers after sporadic and familial colorectal cancer
    Hemminki, K
    Li, XJ
    Dong, CH
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2001, 10 (07) : 793 - 798
  • [36] Increased Risk of Second Primary Cancers After a Diagnosis of Melanoma
    Bradford, Porcia T.
    Freedman, Michal
    Goldstein, Alisa M.
    Tucker, Margaret A.
    [J]. ARCHIVES OF DERMATOLOGY, 2010, 146 (03) : 265 - 272
  • [37] Increased risk of second primary cancers after diagnosis of melanoma
    Bradford, P. T.
    Freedman, D. M.
    Goldstein, A. M.
    Tucker, M. A.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 : S138 - S138
  • [38] Risk estimation of second primary cancers after breast radiotherapy
    Santos, Alexandre M. C.
    Marcu, Loredana G.
    Wong, Chia M.
    Bezak, Eva
    [J]. ACTA ONCOLOGICA, 2016, 55 (11) : 1331 - 1337
  • [39] Second primary cancers after in situ and invasive cervical cancer
    Levi, F
    Te, VC
    Randimbison, L
    La Vecchia, C
    [J]. EPIDEMIOLOGY, 2001, 12 (02) : 281 - 282
  • [40] Risk of second primary cancers after radiotherapy for prostate cancer
    Hegemann, N. S.
    Ganswindt, U.
    Engel, J.
    Belka, C.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S158 - S158